Charles Kunsch

Chuck Kunsch, PhD - Biosketch

Chuck joins Dreavent with more than 30 years of leadership in R&D, business development and life science venture investing and is passionate about working with entrepreneurs and innovators to advance discoveries that bring novel therapeutics to patients. He has broad experience in sourcing, evaluation and transacting early-stage investments and business development partnerships through leveraging a well-established network. Chuck spent over 10 years as Managing Director at AbbVie Ventures where he led investments in and served on the boards of numerous companies including Prevail (acquired by Lilly), Tidal Therapeutics (acquired by Sanofi), FireCyte Therapeutics, DG Medicines, Disc Medicine (NASDAQ: IRON), Kojin Therapeutics, Accent Therapeutics and Quanta Therapeutics among others. Prior to AbbVie, Chuck was Vice President of Biology at AtheroGenics, Inc leading teams to advance several programs into the clinic for cardiovascular disease, rheumatoid arthritis and asthma. He started his career at Human Genome Sciences managing a team of scientists conducting whole-genome sequencing and analysis of several human pathogenic bacteria.

Chuck obtained his Ph.D. from The Pennsylvania State University College of Medicine and completed his post-doctoral fellowship at the Roche Institute of Molecular Biology. He is an author on more than 60 scientific publications and inventor on dozens of patents. Chuck currently serves on the Supervisory Board of Captor Therapeutics, is a member of the Board of Trustees for The Pennsylvania State Research Foundation and is Vice Chairman of the Board of Trustees for the Massachusetts Biomedical Initiatives.